Skip to search formSkip to main content

GYKI 53405

Known as: GYKI-53405 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
RationaleAlthough emerging number of data supports the role of glutamate receptors and the potential of their antagonists in… Expand
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
2007
2007
BACKGROUND AND PURPOSE Blockade of AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors is a good treatment… Expand
Is this relevant?
2007
2007
Although levodopa is the current "gold standard" for treatment of Parkinson's disease, there has been disputation on whether AMPA… Expand
Is this relevant?
2006
2006
EGIS-8332 and GYKI 53405 are selective, non-competitive AMPA (2-amino-3[3-hydroxy-5-methyl-4-isoxazolyl] propionic acid… Expand
Is this relevant?
2004
2004
Antagonists of 2-amino-3(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA) receptors can considerably reduce brain damage… Expand
Is this relevant?
2004
2004
The release of [3H]dopamine was measured in rat corticostriatal slice preparations that contained the striatum and the adjacent… Expand
Is this relevant?
2001
2001
GYKI 52466 [1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine], a non-competitive AMPA [alpha-amino-3-hydroxy-5… Expand
Is this relevant?
1996
1996
1. The 2,3-benzodiazepines GYKI 52466, GYKI 53405 and GYKI 53655 antagonized AMPA-induced currents in cultured superior… Expand
Is this relevant?